Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aciphex Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

NCT02475161
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Rabeprazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658775
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Moline, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

NCT00648349
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Delayed-Release Tablets 20 mg, Aciphex® Delayed-Release Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

NCT06264440
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB122, Rabeprazole
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Surufatinib DDI With a PPI and a CYP3A Inducer

NCT04510649
View directory record Official record
Conditions
Healthy
Interventions
Part A, Part B
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

NCT01398046
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib, Dasatinib plus Rabeprazole, Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

NCT01153659
View directory record Official record
Conditions
Healthy
Interventions
E3810, Aciphex (rabeprazole), Nexium (esomeprazole)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers

NCT00999128
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GDC-0941, rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Gastric pH on the Pharmacokinetics of Atazanavir

NCT01759875
View directory record Official record
Conditions
Healthy
Interventions
Ritonavir-boosted Atazanavir, Ritonavir-boosted Atazanavir plus Rabeprazole, Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

NCT04488016
View directory record Official record
Conditions
Bioavailability, B-cell Lymphoid Cancer
Interventions
Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

NCT05918822
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

NCT01287091
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0980, rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 Food Effect and Proton Pump Inhibitor Study

NCT05571787
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
HMPL-523, Rabeprazole
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619
View directory record Official record
Conditions
Healthy
Interventions
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers

NCT01237353
View directory record Official record
Conditions
Pharmacodynamic
Interventions
betaine hydrochloride, Rabeprazole
Dietary Supplement · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 59 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 2 Interventional

Post-nasal Drainage as an Extraesophageal Manifestation of Reflux

NCT00199953
View directory record Official record
Conditions
Postnasal Drainage
Interventions
Rabeprazole 20 mg twice a day for 90-day period treatment
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 2Phase 3 Interventional

Trial of Electrosurgical Incision Versus Bougie Dilation of Symptomatic Lower Esophageal (Schatzki's) Rings

NCT00204750
View directory record Official record
Conditions
Lower Esophageal Ring, Dysphagia
Interventions
Bougie Dilation, Needle-knife incision
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 3, 2008 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

NCT07563894
View directory record Official record
Conditions
Healthy
Interventions
PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

NCT00839306
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole ER, Ranitidine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Moline, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 2 Interventional

Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00222170
View directory record Official record
Conditions
Esophageal Reflux
Interventions
Rabeprazole
Drug
Lead sponsor
University of Kansas
Other
Eligibility
19 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

NCT05407675
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986408, Nivolumab, Ipilimumab, Platinum-doublet chemotherapy, Rabeprazole
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Sleep Disorders and Gastroesophageal Reflux Disease (GERD)

NCT00287391
View directory record Official record
Conditions
Insomnia, GERD
Interventions
Rabeprazole
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2007 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

NCT07329972
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 5, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

NCT06417229
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986365, Rabeprazole
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 5, 2026, 3:44 PM EDT